Brief: Invion Secures Non-Dilutive Funding From Hanlim Pharm And Korean Government Research Fund
23/12/2025 01:14
Dec 23 (Reuters) - Invion Ltd IVX.AX: NON-DILUTIVE FUNDING SECURED FROM HANLIM PHARM AND KOREAN GOVERNMENT RESEARCH FUND FOR ESOPHAGEAL CANCER PRECLINICAL PROGRAM WORK PROGRAM ESTIMATED TO BE WORTH UP TO A$2 MILLION Further company coverage: IVX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invion
See all newsAustralia's Invion rises after securing clinical trial funding arrangements
Brief: Invion Ltd Says Funding Agreements Cover Up To 85% Of Clinical Trials Costs
Brief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Australia's Invion enters ophthalmology agreement with Sangmyung Innovation
Brief: Invion Signs First Ophthalmology Collaboration Agreement With Sangmyung Innovation